argenx SE (ARGX)
NASDAQ: ARGX · Real-Time Price · USD
840.50
-7.22 (-0.85%)
At close: Jan 30, 2026, 4:00 PM EST
840.32
-0.18 (-0.02%)
Pre-market: Feb 2, 2026, 4:36 AM EST
argenx SE Revenue
argenx SE had revenue of $1.15B in the quarter ending September 30, 2025, with 95.51% growth. This brings the company's revenue in the last twelve months to $3.69B, up 93.18% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.52% growth.
Revenue (ttm)
$3.69B
Revenue Growth
+93.18%
P/S Ratio
13.89
Revenue / Employee
$2,303,490
Employees
1,599
Market Cap
51.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.25B | 983.45M | 77.52% |
| Dec 31, 2023 | 1.27B | 823.33M | 184.91% |
| Dec 31, 2022 | 445.27M | -94.15M | -17.45% |
| Dec 31, 2021 | 539.42M | 474.51M | 731.01% |
| Dec 31, 2020 | 64.91M | -29.11M | -30.96% |
| Dec 31, 2019 | 94.03M | 60.43M | 179.91% |
| Dec 31, 2018 | 33.59M | -15.91M | -32.14% |
| Dec 31, 2017 | 49.50M | 31.46M | 174.30% |
| Dec 31, 2016 | 18.05M | 7.24M | 66.96% |
| Dec 31, 2015 | 10.81M | 4.30M | 66.15% |
| Dec 31, 2014 | 6.51M | -719.25K | -9.95% |
| Dec 31, 2013 | 7.23M | 3.23M | 80.65% |
| Dec 31, 2012 | 4.00M | 11.07K | 0.28% |
| Dec 31, 2011 | 3.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Regeneron Pharmaceuticals | 14.34B |
| Vertex Pharmaceuticals | 11.72B |
| BeOne Medicines AG | 4.97B |
| Incyte | 4.81B |
| Genmab | 3.85B |
| BioNTech SE | 3.70B |
| Alnylam Pharmaceuticals | 3.21B |
| Royalty Pharma | 2.35B |
ARGX News
- 3 days ago - Artisan Global Opportunities Fund Q4 2025 Portfolio Update - Seeking Alpha
- 13 days ago - Artisan Mid Cap Fund Q4 2025 Performance Discussion And Portfolio Activity - Seeking Alpha
- 20 days ago - argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART in AChR-Ab Seronegative gMG - GlobeNewsWire
- 20 days ago - argenx SE (ARGX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 21 days ago - argenx Highlights 2026 Strategic Priorities - GlobeNewsWire
- 26 days ago - Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Month - Benzinga
- 27 days ago - argenx to Present at 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - argenx Announces Leadership Transition Marking Next Evolution of Growth - GlobeNewsWire